Sudan Loganathan
Stock Analyst at Stephens & Co.
(0)
# 4691
Out of 5,218 analysts
23
Total ratings
26.32%
Success rate
-19.09%
Average return
Main Sectors:
Top Industries:
Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
Elevation Oncology | Reiterates: Overweight | 5 5 | 0.64 | 681.25% | 2 | Dec 6, 2024 | |
Actinium Pharma | Reiterates: Overweight | 5 5 | 1.21 | 313.22% | 2 | Nov 19, 2024 | |
Catalyst Pharmaceuti... | Initiates Coverage On: Overweight | 35 | 21.36 | 63.86% | 1 | Nov 18, 2024 | |
IDEAYA Biosciences | Initiates Coverage On: Overweight | 51 | 25.19 | 102.46% | 1 | Nov 18, 2024 | |
C4 Therapeutics | Initiates Coverage On: Equal-Weight | 4 | 4.38 | -8.68% | 1 | Nov 18, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 65 | 41.98 | 54.84% | 1 | Nov 18, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 55 | 19.42 | 183.21% | 1 | Nov 18, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Equal-Weight | 25 | 13.8 | 81.16% | 1 | Nov 8, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 6 | 1.87 | 220.86% | 1 | Nov 8, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 30 | 12.59 | 138.28% | 1 | Nov 8, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 13 | 1.63 | 697.55% | 1 | Nov 8, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 23 29 | 35.01 | -17.17% | 2 | Oct 30, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 31 31 | 20.21 | 53.39% | 2 | Oct 14, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 25 25 | 12.09 | 106.78% | 2 | Aug 6, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 5 5 | 0.43 | 1062.79% | 2 | May 24, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 140 | 93.28 | 50.09% | 1 | May 14, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 20 | 2.29 | 773.36% | 1 | May 14, 2024 |